155
Participants
Start Date
April 30, 2006
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
ipilimumab (MDX-010, BMS-734016)
IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Little Rock
San Francisco
Santa Monica
Chicago
Park Ridge
Goshen
Hazard
Albuquerque
New York
Portland
Greenville
Knoxville
Dallas
Charlottesvillle
Local Institution, Salzburg
Local Institution, Vienna
Local Institution, Wels
Local Institution, Turku
Local Institution, Genova
Local Institution, Meldola
Local Institution, Milan
Local Institution, Napoli
Local Institution, Padua
Local Institution, Siena
Local Institution, Torino
Local Institution, Oslo
Local Institution, Lodz
Local Institution, Poznan
Local Institution, Wroclaw
Local Institution, Barnaul
Local Institution, Moscow
Local Institution, Murmansk
Local Institution, Ryazan
Local Institution, Saint Petersburg
Local Institution, Samara
Local Institution, Stavropol
Local Institution, Veliky Novgorod
Local Institution, Voronezh
Local Institution, Barcelona
Local Institution, Madrid
Local Institution, Málaga
Local Institution, Santa Cruz de Tenerife
Local Institution, Valencia
Local Institution, Gothenburg
Local Institution, Lund
Local Institution, Stockholm
Local Institution, Uppsala
Local Institution, Cherkassy
Local Institution, Dnipropetrovsk
Local Institution, Kiev
Local Institution, Lviv
Local Institution, Sumy
Local Institution, Uzhhorod
Lead Sponsor
Collaborators (1)
Medarex
INDUSTRY
Bristol-Myers Squibb
INDUSTRY